Walleye Capital
CRSP icon

Walleye Capital’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$665K Buy
12,200
+5,800
+91% +$306K ﹤0.01% 2467
2026
Q1 		$304K Sell
6,400
-7,000
-52% -$369K ﹤0.01% 3055
2025
Q4 		$703K Buy
13,400
+5,500
+70% +$329K ﹤0.01% 2708
2025
Q3 		$512K Sell
7,900
-77,100
-91% -$4.43M ﹤0.01% 2590
2025
Q2 		$4.13M Sell
85,000
-7,000
-8% -$271K 0.02% 996
2025
Q1 		$3.13M Buy
92,000
+57,300
+165% +$2.43M 0.01% 1103
2024
Q4 		$1.37M Buy
34,700
+27,800
+403% +$1.31M ﹤0.01% 2109
2024
Q3 		$324K Buy
6,900
+200
+3% +$10.1K ﹤0.01% 3670
2024
Q2 		$362K Sell
6,700
-7,700
-53% -$445K ﹤0.01% 3801
2024
Q1 		$982K Sell
14,400
-16,600
-54% -$1.19M ﹤0.01% 2609
2023
Q4 		$1.94M Buy
31,000
+9,600
+45% +$531K ﹤0.01% 1805
2023
Q3 		$971K Hold
21,400
– – ﹤0.01% 2276
2023
Q2 		$1.2M Buy
21,400
+6,700
+46% +$380K ﹤0.01% 1702
2023
Q1 		$665K Buy
14,700
+2,900
+25% +$141K 0.01% 1461
2022
Q4 		$480K Buy
11,800
+700
+6% +$37.1K 0.01% 1482
2022
Q3 		$725K Buy
+11,100
New +$804K 0.01% 1187
2019
Q4 		– Sell
-8,700
Closed -$357K – 1875
2019
Q3 		$357K Buy
8,700
+7,300
+521% +$349K 0.02% 897
2019
Q2 		$66K Hold
1,400
– – 0.01% 1322
2019
Q1 		$50K Buy
+1,400
New +$48.4K 0.01% 1206

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's CRSP Position: Q2 2026 in Review

Walleye Capital increased its CRISPR Therapeutics (CRSP) stake by 2,538% in Q2 2026, buying an estimated $1.22M and bringing the position to 24,136 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1886.

Walleye Capital first reported a position in CRSP in Q3 2019 and has held it in 10 quarters since. The position peaked at $5.39M in Q1 2025. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Walleye Capital held 24,136 shares of CRISPR Therapeutics worth $1.32M as of Q2 2026.
  • Walleye Capital bought 23,221 CRISPR Therapeutics shares in Q2 2026, an estimated $1.22M.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #1886 holding.
  • Walleye Capital first reported a position in CRISPR Therapeutics in Q3 2019 and has held it in 10 quarters since.
  • Walleye Capital's CRISPR Therapeutics position peaked at $5.39M in Q1 2025.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.